Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

6(85.7%)

Phase 2

1(14.3%)

7Total

Phase 1(6)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01094613Phase 1Terminated

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Role: lead

NCT01433432Phase 2Withdrawn

Open Label Extension Study to Protocol C2/13/DR-6MP-02

Role: lead

NCT00774982Phase 1Completed

Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients

Role: lead

NCT00464958Phase 1Terminated

One Year Extension Study To Protocol C2/5/TZ:MS-05

Role: lead

NCT00358293Phase 1Completed

Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity

Role: lead

NCT00287157Phase 1Completed

Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)

Role: lead

NCT00287170Phase 1Completed

Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease

Role: lead

All 7 trials loaded